Literature DB >> 18076598

Otomycosis in western Nigeria.

James Fasunla1, Titus Ibekwe, Paul Onakoya.   

Abstract

Otomycosis is a recognized clinical entity in the tropical regions of the world. However, there is scanty information on this disease in some parts of Sub-Saharan Africa. The aim of this study was to determine the prevalence and pattern of etiological agents of otomycosis in western Nigeria. Medical records of patients with otomycosis seen in the Otorhinolaryngology Department of the University College Hospital, Ibadan from 1996-2005 were reviewed for all essential clinical data. Of the 5784 patients with ear diseases, 378 (6.54%) had otomycosis which consisted of 145 (38.36%) males and 233 (61.64%) females. Seventeen patients (4.50%) had recurrence within six months of treatment, 4 (1.06%) had poorly controlled plasma glucose. A significant number of our patients, 52 (13.76%), had prior topical aural antibiotic treatment following misdiagnosis. The predominant etiological agents in our series were Aspergillus niger (48.35%) and Aspergillus fumigatus (33.96%).

Entities:  

Mesh:

Year:  2008        PMID: 18076598     DOI: 10.1111/j.1439-0507.2007.01441.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  18 in total

1.  Otomycosis due to filamentous fungi.

Authors:  Lidia García-Agudo; Pilar Aznar-Marín; Fátima Galán-Sánchez; Pedro García-Martos; Pilar Marín-Casanova; Manuel Rodríguez-Iglesias
Journal:  Mycopathologia       Date:  2011-04-17       Impact factor: 2.574

2.  Otomycosis in central iran: a clinical and mycological study.

Authors:  B Barati; S A R Okhovvat; A Goljanian; M R Omrani
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

3.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

4.  Otomycosis in Jos: Predisposing factors and Management.

Authors:  A S Adoga; A A Iduh
Journal:  Afr J Med Med Sci       Date:  2014-09

5.  Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary.

Authors:  Gyöngyi Szigeti; Sándor Kocsubé; Ilona Dóczi; László Bereczki; Csaba Vágvölgyi; János Varga
Journal:  Mycopathologia       Date:  2012-02-23       Impact factor: 2.574

Review 6.  Otomycosis in the South of Iran with a High Prevalence of Tympanic Membrane Perforation: A Hospital-Based Study.

Authors:  Javad Javidnia; Zahra Ghotbi; Aynaz Ghojoghi; Kavous Solhjoo; Mohamed Mahdi Alshahni; Seyed Ali Jeddi; Bahram Ahmadi; Sadegh Nouripour-Sisakht; Saham Ansari; Gholamreza Shokoohi
Journal:  Mycopathologia       Date:  2022-03-26       Impact factor: 2.574

7.  Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents.

Authors:  Shadman Nemati; Rasool Hassanzadeh; Sina Khajeh Jahromi; Azimeh Delkhosh Nasrollah Abadi
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-18       Impact factor: 2.503

8.  Otomycosis in a Rural Community Attending a Tertiary Care Hospital: Assessment of Risk Factors and Identification of Fungal and Bacterial Agents.

Authors:  Priti Agarwal; Leimapokpam Sumitra Devi
Journal:  J Clin Diagn Res       Date:  2017-06-01

9.  Otomycosis in Adolescent Patients Referred to the Therapeutic Centers in Babol City, Iran.

Authors:  Keivan Kiakojuri; Ramazan Rajabnia; Bahareh Jalili; Soraya Khafri; Saeid Mahdavi Omran
Journal:  Jundishapur J Microbiol       Date:  2015-05-31       Impact factor: 0.747

10.  Etiologic Agents of Otomycosis in the North-Western Area of Iran.

Authors:  Abdolhassan Kazemi; Maryam Majidinia; Abbasali Jaafari; Seyyed Amin Ayatollahi Mousavi; Ali Zarei Mahmoudabadi; Hossein Alikhah
Journal:  Jundishapur J Microbiol       Date:  2015-09-08       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.